IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4602
Positioning
Market Dominance
Manufacturing
Medical Equipment
$34M
Paul R. Gudonis
MyoPro is a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$MYO MYOMO, INC. | 29 | 42 | 19 | 12 | - | - | -87.0% | -37.4% | 67.3% | -32.2% | -32.5% | 34.2% | 0.0% | 17.0x | $34M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
MYOMO, INC. (MYO) receives a "Avoid" rating with a composite score of 28.8/100. It ranks #4602 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Paul R. Gudonis
Chief Executive Officer
Labor Force
90
42
32
36
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for MYO
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MYO.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -87.0% (sector -2.5%)
GM 67% vs sector 43%, OM -32% vs sector 1%
Capital turnover N/A, R&D intensity 18.0%
Rev growth 34%, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags MYOMO, INC. with an Avoid rating, assigning a composite score of 28.8/100 and 1 out of 5 stars. Ranked #4602 of 7,333 stocks, MYO falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
MYO's quality score of 42/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -87.0% (sector avg: -2.5%), gross margins of 67.3% (sector avg: 42.5%), net margins of -32.5% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
MYO registers a value score of just 19/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.92x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
MYOMO, INC.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 34.2% vs. a sector average of 5.9% and a return on assets of -37.4% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
MYOMO, INC. is experiencing notably weak momentum with a score of just 12/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 34.2% year-over-year, while a beta of 1.14 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
MYO's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.14 and a debt-to-equity ratio of 17.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
MYOMO, INC.'s short interest score of 13/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 17.00x), micro-cap liquidity risk. At $34M (micro-cap), MYO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
MYOMO, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4602 of 7,333 overall (37th percentile). Key comparisons include ROE of -87.0% trailing the -2.5% sector median and operating margins of -32.2% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MYO currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (12) would have the largest impact on the composite score.
ROE 3408% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 58% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 2593% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate MYOMO, INC. (MYO) as Avoid with a composite score of 28.8/100 at a current price of $0.65. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in quality (42th percentile) and stability (36th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (12th percentile) and value (19th percentile) tempers our overall conviction. We assign a Narrow Moat rating (40/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
MYOMO, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 28.8/100 places it at rank #4602 in our full 7,333-stock universe. At $34M in market capitalization, MYOMO, INC. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 34%, though momentum at the 12th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 67% (+24.8pp vs sector) narrow to operating margins of -32% (-33.4pp vs sector) and net margins of -32.5%, yielding a gross-to-net conversion rate of -48%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.65, MYOMO, INC. is trading at a premium to fundamental value. Our value factor score of 19/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 1.9x, P/S of 0.7x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 67% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 34% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (17% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 28.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -32.5% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to MYOMO, INC.. Key risk factors include current negative profitability (net margin -32.5%), below-average price stability (36th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -32.5%); below-average price stability (36th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 36th percentile and quality factor at the 42th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 67% provide a buffer against cost pressures; conservative leverage (17% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate MYOMO, INC.'s capital allocation as Poor. Key concerns include low returns on equity (-87.0%), negative profitability, weak asset returns (ROA -37.4%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — MYOMO, INC. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, MYOMO, INC. receives a Avoid rating with a composite score of 28.8/100 (rank #4602 of 7,333). Our quantitative framework assigns a Narrow Moat (40/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on MYOMO, INC. at this time. The combination of the current quantitative profile, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign MYOMO, INC. a Narrow Moat rating with a composite moat score of 40/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that MYOMO, INC. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 12.7/20.
The strongest moat sources are growth durability (12.7/20) and margin superiority (12.2/20). Rev growth 34%, 9yr history. GM 67% vs sector 43%, OM -32% vs sector 1%. These pillars form the core of MYOMO, INC.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and reinvestment efficiency (6.3/20). ROE proxy -87.0% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect MYOMO, INC.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 67% providing a solid profitability foundation, robust top-line growth of 34% expanding the revenue base. The margin cascade from 67% gross to -32% operating to -32.5% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 42th percentile.
The margin profile shows gross margins of 67%, operating margins of -32%, net margins of -32.5%. Return metrics include ROE of -87.0% and ROA of -37.4%. Relative to the Manufacturing sector, gross margins are 24.8 percentage points above the sector median of 43%, and ROE of -87.0% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 17%, revenue growth of 34%. The sector median D/E is 0%, putting MYOMO, INC. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Weak momentum (12th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Above 50MA
37.18%
Net New Highs
+51081
Myomo Inc (MYO) reports robust revenue growth in Germany, but faces domestic hurdles with decreased margins and increased operating expenses.

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-than-expected earnings and sales results for its second quarter on Thursday. The company said it expects fiscal year 2024 non-GAAP income from operations between $395 million and $400 million and net income per share between $2.73 and $2.77. Zscaler shares fell 10.1% to $217.43 on Friday. Here are some other stocks moving in today's mid-day session. Gainers BioVie Inc. (NASDAQ: BIVI) shares climbed 96.1% to $2.4319. BioVie's Ne3107 demonstrated potential improvements in motor and non-motor symptoms for Parkinson's disease patients and may be realigning physiological processes for Alzheimer's patients. Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) gained 68.4% to $3.4350. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder. Cardiff Oncology, Inc. (NASDAQ: CRDF) shares rose 41.5% to $2.50 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial. Minim, Inc. (NASDAQ: MINM) shares rose 41.4% to $6.09. On Feb. 20, Minim entered into an employment agreement with David Lazar to engage him as CEO, CFO, following resignation of Jeremy Hitchcock. The RealReal, Inc. (NASDAQ: REAL) gained 39.1% to $2.4613 following upbeat quarterly results. Nxu, Inc. (NASDAQ: NXU) shares gained 36.4% to $1.09 after the company announced it successfully charged a Tesla Cybertruck on Feb. 26. Jaguar Health, Inc. (NASDAQ: JAGX) climbed 35.3% to $0.0798. Dell Technologies Inc. (NYSE: DELL) rose 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%. Sweetgreen, Inc. (NYSE: SG) gained 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results. MMTec, Inc. (NASDAQ: MTC) climbed 25% to $1.61. Everbridge, Inc. (NASDAQ: EVBG) rose 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo. NetApp, Inc. (NASDAQ: NTAP) shares gained 24.4% to $110.85 after the company reported better-than-expected third-quarter financial results ...

Gainers Alset Capital Acquisition Corp. (NASDAQ: ACAX) shares climbed 66.2% to $12.93. YS Biopharma Co., Ltd. (NASDAQ: YS) shares jumped 57% to $1.1850 after the company announced the purchase of shares by company officers. Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 42.1% to $1.7757 after falling over 9% on Thursday. The company, on Thursday, issued a second-quarter business update. Cano Health, Inc. (NYSE: CANO) surged 41% to $0.3250. Cano Health recently appointed Mark Kent as permanent Chief Executive Officer. Affirm Holdings, Inc. (NASDAQ: AFRM) gained 24.7% to $17.23 after the company reported better-than-expected fourth-quarter financial results and issued guidance. VinFast Auto Ltd. (NASDAQ: VFS) jumped 24% to $61.00. Hibbett, Inc. (NASDAQ: HIBB) gained 21.8% to $44.88 following upbeat quarterly earnings. Lendway, Inc. (NASDAQ: LDWY) jumped 19.4% to $5.06. InnSuites Hospitality Trust (NYSE: IHT) gained 18.6% to $1.7082. Genius Group Limited (NYSE: GNS) surged 17.7% to $1.33. Precigen, Inc. (NASDAQ: PGEN) jumped 15.7% to $1.77. Bionomics Limited (NASDAQ: BNOX) surged 15.4% to $1.7305. American Software, Inc. (NASDAQ: AMSWA) gained 10% to $11.81 following upbeat quarterly earnings. Better Home & Finance Holding Co (NASDAQ: BETR) shares rose 7.8% to $1.2398 after dipping 93% on ...

Gainers YS Biopharma Co., Ltd. (NASDAQ: YS) shares gained 57.6% to $1.19 in pre-market trading after the company announced the purchase of shares by company officers. Better Home & Finance Holding Co (NASDAQ: BETR) shares rose 35.6% to $1.56 in pre-market trading after dipping 93% on Thursday. Crown ElectroKinetics Corp. (NASDAQ: CRKN) rose 25.6% to $1.57 in pre-market trading after falling over 9% on Thursday. The company, on Thursday, issued a second-quarter business update. SciSparc Ltd. (NASDAQ: SPRC) shares climbed 22% to $0.1940 in pre-market trading. SciSparc recently announced pricing of $1.3 million underwritten public offering of 6.5m shares at $0.20 per share. Orgenesis Inc. (NASDAQ: ORGS) rose 15.2% to $0.50 in pre-market trading after falling 28% on Thursday. Marin Software Incorporated (NASDAQ: MRIN) shares rose 12.9% to $0.4990 in pre-market trading after falling ...

Upgrades According to Susquehanna, the prior rating for Caesars Entertainment Inc (NASDAQ:CZR) was changed from Negative to Neutral. For the first quarter, Caesars Entertainment had an EPS of $0.63, compared to year-ago quarter EPS of $2.11. At the moment, the stock has a 52-week-high of $56.75 and a 52-week-low of $31.31. Caesars Entertainment closed at $41.69 at the end of the last trading period. According to Baird, the prior rating for NVIDIA Corp (NASDAQ:NVDA) was changed from Neutral to Outperform. For the first quarter, NVIDIA had an EPS of $1.09, compared to year-ago quarter EPS of $1.36. At the moment, the stock has a 52-week-high of $318.28 and a 52-week-low of $108.14. NVIDIA closed at $305.38 at the end of the last trading period. For NVIDIA Corp (NASDAQ:NVDA), Craig-Hallum upgraded the previous rating of Hold to Buy. For the first quarter, NVIDIA had an EPS of $1.09, compared to year-ago quarter EPS of $1.36. At the moment, the stock has a 52-week-high of $318.28 and a 52-week-low of $108.14. NVIDIA closed at $305.38 at the end of the last trading period. Janney Montgomery Scott upgraded the previous rating for CVB Financial Corp (NASDAQ:CVBF) from Neutral to Buy. For the first quarter, CVB Financial had an EPS of $0.42, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of $29.25 and a 52-week-low of $10.66. At the end of the last trading period, CVB Financial closed at $12.37. For NVIDIA Corp (NASDAQ:NVDA), Wedbush upgraded the previous rating of Neutral to Outperform. For the first quarter, NVIDIA had an EPS of $1.09, compared to year-ago quarter EPS of $1.36. At the moment, the stock has a 52-week-high of $318.28 and a 52-week-low of $108.14. NVIDIA closed at $305.38 at the end of the last trading period. Citigroup upgraded the previous rating for Carnival Corp (NYSE:CCL) from Neutral to Buy. In the first quarter, Carnival showed an EPS of $0.55, compared to $1.66 from the year-ago quarter. The current stock performance of Carnival shows a 52-week-high of $14.20 and a 52-week-low of $6.12. Moreover, at the end of the last trading period, the closing price was at $10.67. According to Wells Fargo, the prior rating for Leidos Holdings Inc (NYSE:LDOS) was changed from Equal-Weight to Overweight. For the first quarter, Leidos Holdings had an EPS of $1.47, compared to year-ago quarter EPS of $1.58. At the moment, the stock has a 52-week-high of $110.86 and a 52-week-low of $76.58. Leidos Holdings closed at $80.65 at the end of the last trading period. Wells Fargo upgraded the previous rating for Dycom Industries Inc (NYSE:DY) from Equal-Weight to Overweight. In the first quarter, Dycom Industries showed an EPS of $1.73, compared to $0.65 from the year-ago quarter. At the moment, the stock has a 52-week-high of $122.09 and a 52-week-low of $77.33. Dycom Industries closed at $97.02 at the end of the last trading period. According to RBC Capital, the prior rating for Toll Brothers Inc (NYSE:TOL) was changed from Sector Perform to Outperform. Toll Brothers earned $2.85 in the second quarter, compared to $1.85 in the year-ago quarter. The current stock performance of Toll Brothers shows a 52-week-high of $67.54 and a 52-week-low of $39.63. Moreover, at the end of the last trading period, the closing price was at $65.09. For PPL Corp (NYSE:PPL), Credit Suisse upgraded the previous rating of Neutral to Outperform. PPL earned $0.48 in the first quarter, compared to $0.41 in the year-ago quarter. The stock has a 52-week-high of $31.74 and a 52-week-low of $23.47. At the end of the last trading period, PPL closed at $26.44. Daiwa Capital upgraded the previous rating for Ford Motor Co (NYSE:F) from Underperform to Neutral. For the first quarter, Ford Motor had an ...Full story available on Benzinga.com